VIP会员
| 中文名: | 巴非替尼;4-[[(3s)-3-二甲基氨基吡咯烷-1-基]甲基]-N-[4-甲基-3-[(4-嘧啶-5-基嘧啶-2-基)氨基]苯基]-3-(三氟甲基)苯甲酰胺 |
| 中文别名: | N-[3-([5,5‘-联嘧啶]-2-基氨基)-4-甲基苯基]-4-[[(3S)-3-(二甲基氨基)-1-吡咯烷基]甲基]-3-(三氟甲基)苯甲酰胺;巴非替尼 |
| 英文名称： | Bafetinib(INNO-406) |
| 英文别名： | Bafetinib(INNO-406) |
| CAS No.: | 887650-05-7 |
| 分子式: | C30H31F3N8O |
| 分子量: | 576.62 |
| 性状: | |
| 储存: | |
| 安全术语: | |
| 风险术语: | |
| 危险品标志: | |
| 危险品运输编号: | |
| 用途: | Bafetinib (INNO-406) is an orally available, dual Abl/Lyn kinase inhibitor that is up to 55-times more potent than imatinib in Bcr-Abl cell lines. Numerous Bcr-Abl mutant proteins (not T315I) are sensitive to INNO-406 in vitro. INNO-406 demonstrates specific Src kinase activity against Lyn kinase. [1] |
粤公网安备44196802000105号
400-6226-992